<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962477</url>
  </required_header>
  <id_info>
    <org_study_id>202107016</org_study_id>
    <nct_id>NCT04962477</nct_id>
  </id_info>
  <brief_title>Understanding Host-pathogen Interaction in the Respiratory Mucosa During Pregnancy</brief_title>
  <official_title>Understanding Host-pathogen Interaction in the Respiratory Mucosa During Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical presentation of the ongoing coronavirus disease-19 (COVID-19) pandemic in&#xD;
      pregnant women is unique with more asymptomatic infection, higher morbidity when symptomatic,&#xD;
      yet without a difference in mortality rate. This is strikingly different from the high&#xD;
      mortality observed during the past influenza A pandemics. Though both influenza A virus (IAV)&#xD;
      and SARS-CoV-2 are single-stranded RNA viruses, the exquisite vulnerability of pregnant women&#xD;
      to influenza A but not COVID-19 remains a mystery. Our objective, therefore, is to determine&#xD;
      the mechanisms that predispose pregnant women to severe influenza A but confer protection&#xD;
      against SARS-CoV-2 infection by examining the viral entry factors and innate immune response&#xD;
      mechanisms in the nasal epithelium of pregnant vs. non-pregnant age-matched women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression of viral entry factors</measure>
    <time_frame>Dec 2021</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expression of genes involved in innate immune response and host-pathogen interaction</measure>
    <time_frame>Dec 2021</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Innate Inflammatory Response</condition>
  <arm_group>
    <arm_group_label>Pregnant</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-pregnant</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nasal brush sampling</intervention_name>
    <description>Nasal brush samples will be collected from the inferior turbinate using standardized techniques after local anesthetic application. After clearing the mucus from the nasal cavity by asking the patient to blow their nostrils twice followed by local anesthetic spray application, nasal brush samples will be collected from the inferior turbinate of each nostril with dedicated soft cytology brushes and pooled together for molecular biological experiments. Simultaneously, 10 mL of peripheral blood will be collected for immunophenotyping.</description>
    <arm_group_label>Non-pregnant</arm_group_label>
    <arm_group_label>Pregnant</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal brush samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant cohort: pregnant women in their third trimester admitted to the hospital for any&#xD;
        elective procedure (cesarean delivery, labor induction etc.,)&#xD;
&#xD;
        Non-pregnant cohort: age-matched female volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, uncomplicated pregnant subjects in the third trimester ((≥ 28 ≤ 41 weeks'&#xD;
             gestation)&#xD;
&#xD;
          -  Healthy non-pregnant adult female volunteers between the ages of 18 - 45 years.&#xD;
&#xD;
          -  Between 18-45 years old&#xD;
&#xD;
          -  Able to provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in labor&#xD;
&#xD;
          -  Critically ill patients needing intubation and mechanical ventilation&#xD;
&#xD;
          -  Patients with fever or influenza-like illness&#xD;
&#xD;
          -  H/o epistaxis or rhinosinusitis&#xD;
&#xD;
          -  Nasal polyposis and deviated nasal septum&#xD;
&#xD;
          -  Preeclampsia and chronic hypertension&#xD;
&#xD;
          -  Use of anti-hypertensives&#xD;
&#xD;
          -  Ongoing seasonal allergy&#xD;
&#xD;
          -  H/o asthma&#xD;
&#xD;
          -  Recent recovery from SARS-CoV-2 or influenza A infection (≤ 4 weeks)&#xD;
&#xD;
          -  Recent receipt of either COVID-19 or influenza A vaccine (≤ 4 weeks)&#xD;
&#xD;
          -  Use of immunosuppressive medications&#xD;
&#xD;
          -  Use of inhaled corticosteroids&#xD;
&#xD;
          -  Use of hormonal contraceptives in non-pregnant population&#xD;
&#xD;
          -  Allergy to local anesthetic&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only females are eligible for the study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arvind Palanisamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arvind Palanisamy, MD</last_name>
    <phone>8572250088</phone>
    <email>arvind.palanisamy@wustl.edu</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Washington University School of Medicine</investigator_affiliation>
    <investigator_full_name>Arvind Palanisamy</investigator_full_name>
    <investigator_title>Associate Professor of Anesthesiology, Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

